StockNews.com assumed coverage on shares of Diffusion Pharmaceuticals (NASDAQ:DFFN – Get Rating) in a research report sent to investors on Monday morning. The brokerage issued a sell rating on the stock.
Separately, HC Wainwright reaffirmed a neutral rating on shares of Diffusion Pharmaceuticals in a research note on Thursday, April 7th.
Shares of DFFN stock opened at $0.24 on Monday. The stock has a 50-day simple moving average of $0.26 and a 200 day simple moving average of $0.34. Diffusion Pharmaceuticals has a fifty-two week low of $0.20 and a fifty-two week high of $0.86. The stock has a market capitalization of $24.64 million, a P/E ratio of -0.93 and a beta of 1.46.
Diffusion Pharmaceuticals Company Profile (Get Rating)
Diffusion Pharmaceuticals Inc, a biopharmaceutical company, develops novel therapies that enhance the body's ability to deliver oxygen. Its lead product candidate is Trans Sodium Crocetinate that is developed to enhance the diffusion of oxygen to tissues, as well as to treat COVID-19 disease. The company is also developing DFN-529, a phosphoinositide 3-kinase/Akt/mechanistic target of rapamycin pathway inhibitor.
- Get a free copy of the StockNews.com research report on Diffusion Pharmaceuticals (DFFN)
- 3 Stocks Down Big in ’22 That Are Worth Buying
- Schnitzer Steel Stock Has Value Down Here
- 3 Undervalued Stocks The Insiders Are Buying
- The Market For Gamestop Is Near A Turning Point
- PayPal Stock is Still Ready for Bargain Hunting
Receive News & Ratings for Diffusion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diffusion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.